NovoCure's Pancreatic Pivot: Record Quarter, Positive EBITDA, and a KRAS Bet
A focused clinical strategy and a strong Optune Pax launch signal a turning point for the medical-device maker.
NVCR · Earnings Call · 2026-07-23
Record Quarter, Fundamental Shift
NovoCure’s Q2 2026 report landed with an air of vindication: “This morning, we reported our second quarter 2026 results, and I am pleased to say this was our strongest commercial quarter to date.” — William Doyle, Executive Chairman · 2026-07-23 CEO Frank Leonard wasted no time framing a bigger shift — “We are entering a new phase of clinical development at NovoCure.” — Frank Leonard, Chief Executive Officer · 2026-07-23 The company reported record revenue of $184M (+16% YoY), a surprise positive adjusted EBITDA of $11M (vs -$10M a year ago), and raised full-year revenue guidance to $710-725M. More importantly, the clinical pipeline is being re-engineered around pancreatic cancer and a potential with KRAS inhibitors, with the LUNAR 2 trial scaled back to release ~$90M of costs.Commercial Momentum Across Three Products
The Optune Pax launch is the headline: 418 prescriptions in Q2, 285 active patients, with a 50% repeat-prescriber rate already. As Frank noted, “We are right now looking at about half of our prescriber base has already become a repeat prescriber with the other half having initiated treatment once.” — Frank Leonard, Chief Executive Officer · 2026-07-23 This echoes the enthusiastic reception seen in Q1, when he said “We are seeing -- we're really proud of the Optune Pax launch, both our preparation and also the response from the market.” — Frank Leonard, Chief Executive Officer · 2026-04-30 The CE Mark in Germany adds a second market, and the company is working through case-by-case reimbursement. Meanwhile, Optune Lua in Japan is gaining traction — 64 patients on therapy by June 30, benefiting from national reimbursement secured in March, a stark contrast to the pre-reimbursement phase described last year: “We have received approval for Optune Lua in Japan, but we have not yet received national reimbursement.” — Ashley Cordova, Chief Executive Officer · 2025-10-30 The NCCN’s Category 2A recommendation for Optune Maia in brain metastases from NSCLC adds another potential catalyst, with an FDA decision expected in Q4. The company’s new fill rate conversation is also telling: management is deliberately avoiding over-interpreting early conversion data, preferring to let a larger sample size settle. This measured approach contrasts with the urgency around the strategic pivot.Strategic Pivot: Pancreatic Cancer and the KRAS Combo
This pivot is most visible in the decision to redesign the LUNAR 2 trial in non-small cell lung cancer, trimming endpoints and consolidating sites to save ~$90M. That capital is being redirected to pancreatic programs, including a planned IDE trial pairing TTFields with daraxonrasib in metastatic disease. Chief Innovation Officer Uri Weinberg explained the rationale: “TTFields therapy in the preclinical setting led to the downregulation of c-Myc, which is a master regulator of cancer cell proliferation and metastasis.” — Uri Weinberg, Chief Innovation and Medical Officer · 2026-07-23 The company is also in active negotiations with industry partners to explore earlier-stage combinations, reflecting a broader belief that TTFields can be a backbone therapy alongside novel agents. The shift is not just clinical — it’s financial. CFO Christoph Brackmann highlighted the cost discipline: “We are updating our full year revenue guidance to a range of $710 million to $725 million, representing 8% to 11% growth.” — Christoph Brackmann, Chief Financial Officer · 2026-07-23 R&D costs fell 8% YoY, and the company is confident of keeping R&D flat going forward while investing in the pancreatic franchise.We are entering a new phase of clinical development at NovoCure. Historically, our clinical strategy has focused on areas of significant unmet need and opportunities to establish TTFields in new cancer types. With 3 products approved and under FDA review, we are shifting that mandate to focus on strengthening our market position and broadening labels.